LIGAND PHARMACEUTICALS INC (LGND) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for LIGAND PHARMACEUTICALS INC (LGND): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 62/100 — a percentile rank of LIGAND PHARMACEUTICALS INC’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $6.0B |
| P / E | 30.6× |
| P / S | 20.8× |
| EV / EBITDA | 46.3× |
| Gross margin | 89.9% |
| Operating margin | 32.3% |
| Net margin | 67.9% |
| Return on equity | 20.4% |
| ROIC | 7.2% |
| Revenue growth | 54.9% |
| Debt / equity | 1.2× |
| Dividend yield | 0.0% |
Is LIGAND PHARMACEUTICALS INC overvalued? P/E looks undervalued vs its 5-year range; P/S looks overvalued vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from LIGAND PHARMACEUTICALS INC’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact